Volume 25, Issue 108 (3-2017)                   J Adv Med Biomed Res 2017, 25(108): 129-136 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farshbaf A, Biglari A, Faghihzadeh S, Esmaeilzadeh A. Frequency of CCR5Δ32 Allelic Mutation in Healthy Individuals in Zanjan Province. J Adv Med Biomed Res 2017; 25 (108) :129-136
URL: http://journal.zums.ac.ir/article-1-3965-en.html
1- Dept. of Genetic & Molecular Medicine, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2- Dept. of Biostatistics and Epidemiology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
3- Dept. of Immunology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran , a46reza@zums.ac.ir
Abstract:   (151775 Views)

Background and Objective: CCR5 is known as a main co-receptor in HIV infection. Many studies demonstrated that 32bp deletion in both CCR5 alleles provide natural resistance to HIV infection, so new treatment approaches are based on inducing this resistance by means of gene and cell therapies. This projects aim was the discovery of suitable candidates for new therapeutic strategies in addition to determining the CCR5 Δ32 mutation frequency in healthy individuals in Zanjan province for the first time.

Materials and Methods: Blood samples were collected from 200 healthy individuals in EDTA pre-coated tubes. Genomic DNA was extracted and analyzed for CCR5 Δ32 mutation by GAP-PCR. The allele frequency was calculated using the Hardy-Weinberg equilibrium (HWE).

Results: Our findings showed 1 healthy individual had CCR5 Δ32/Δ32 mutation and the allele frequency of CCR5Δ32 was calculated to be 0.5%.

Conclusion: Results of this study proved previous reports that Iranian populations are more susceptible to HIV/AIDS compared to the European population. Different climate-geographical conditions, migration and positive natural selection could explain various distribution of Δ32 allele frequency in European countries compared to Iran. Consequently, Iranians require more effective and novel therapeutic approaches for HIV infection therapy and could benefit from reducing retro-viral drug restrictions.

Full-Text [PDF 323 kb]   (159603 Downloads)    
Type of Study: Clinical Trials |
Received: 2016/09/28 | Accepted: 2016/09/28 | Published: 2016/09/28

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb